| 1. |
- van der Lely, A J, et al.
(författare)
-
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
- 2001
-
Ingår i: Lancet (London, England). - 0140-6736. ; 358:9295, s. 1754-9
-
Tidskriftsartikel (refereegranskat)abstract
- Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days.Treatment efficacy was assessed by measuring changes in tumour volume by magnetic resonance imaging, and serum growth hormone and IGF-1 concentrations in 152 patients who received pegvisomant by daily subcutaneous injection for up to 18 months. The safety analysis included 160 patients some of whom received weekly injections and are excluded from the efficacy analysis.Mean serum IGF-1 concentrations fell by at least 50%: 467 mg/L (SE 24), 526 mg/L (29), and 523 mg/L (40) in patients treated for 6, 12 and 18 months, respectively (p<0.001), whereas growth hormone increased by 12.5 mg/L (2.1), 12.5 mg/L (3.0), and 14.2 mg/L (5.7) (p<0.001). Of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. In patients withdrawn from pegvisomant (n=45), serum growth hormone concentrations were 8.0 mg/L (2.5) at baseline, rose to 15.2 mg/L (2.4) on drug, and fell back within 30 days of withdrawal to 8.3 mg/L (2.7). Antibodies to growth hormone were detected in 27 (16.9%) of patients, but no tachyphylaxis was seen. Serum insulin and glucose concentrations were significantly decreased (p<0.05). Two patients experienced progressive growth of their pituitary tumours, and two other patients had increased alanine and asparate aminotransferase concentrations requiring withdrawal from treatment. Mean pituitary tumour volume in 131 patients followed for a mean of 11.46 months (0.70) decreased by 0.033 cm(3) (0.057; p=0.353).Pegvisomant is an effective medical treatment for acromegaly.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Modin Larsson, Malin, 1980-, et al.
(författare)
-
Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype
- 2006
-
Ingår i: J Infect Dis. - : Oxford University Press. ; 194:10, s. 1422-1427
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Histo-blood group antigens and secretor status have been associated with susceptibility to Norovirus infections, which suggests that antibody prevalence and titer might correlate with these phenotypes. METHODS: Plasma samples (n = 105) from Swedish blood donors that had been genotyped for secretor (FUT2) and Lewis (Le; FUT3) genotypes and phenotyped for ABO and Le blood groups were analyzed for immunoglobulin G antibody prevalence and titers to norovirus genogroup (GG) II.4. RESULTS: The results showed that nonsecretors (se4128se428) and Lea+b- individuals not only had significantly lower antibody titers than did secretors (P < .0001) and Lea-b+ individuals (P < .0002) but were also significantly more often antibody negative (P < .05). Antibody titers in secretors were not significantly different between individuals of different Le (FUT3) genotypes or different ABO phenotypes. CONCLUSIONS: Nonsecretors and Lea+b- individuals are significantly less prone to be infected with GGII noroviruses. This new information extends previous knowledge and supports the hypothesis that nonsecretors are relatively but not absolutely resistant to norovirus infections.
|
|
| 5. |
- Collins, M D, et al.
(författare)
-
An unusual Streptococcus from human urine, Streptococcus urinalis sp. nov.
- 2000
-
Ingår i: International journal of systematic and evolutionary microbiology. - 1466-5026. ; 50 Pt 3, s. 1173-8
-
Tidskriftsartikel (refereegranskat)abstract
- Biochemical, molecular chemical and molecular genetic studies were performed on an unknown Gram-positive, catalase-negative, chain-forming coccus isolated from the urine of a patient suffering from cystitis. Comparative 16S rRNA gene sequencing showed that the organism is a member of the 'pyogenic subgroup' of the genus Streptococcus and has a close affinity with Streptococcus pyogenes and Streptococcus canis. The unknown coccus was, however, readily distinguished from these species and other streptococci by biochemical tests and electrophoretic analysis of whole-cell proteins. Based on phenotypic and phylogenetic evidence, it is proposed that the unknown bacterium be classified as a new species of the genus Streptococcus, Streptococcus urinalis sp. nov. The type strain of Streptococcus urinalis is CCUG 41590T.
|
|
| 6. |
- Collins, M D, et al.
(författare)
-
Streptococcus ovis sp. nov., isolated from sheep.
- 2001
-
Ingår i: International journal of systematic and evolutionary microbiology. - 1466-5026. ; 51:Pt 3, s. 1147-50
-
Tidskriftsartikel (refereegranskat)abstract
- Seven strains of an unknown Gram-positive catalase-negative chain-forming coccus-shaped organism isolated from clinical specimens from sheep were characterized by phenotypic and molecular taxonomic methods. Comparative 16S rRNA gene sequencing studies demonstrated that the bacterium represents a new sub-line within the genus Streptococcus. The unknown bacterium was readily distinguished from recognized streptococcal species by biochemical tests and electrophoretic analysis of whole-cell proteins. Based on phylogenetic and phenotypic evidence, it is proposed that the unknown bacterium be classified as Streptococcus ovis sp. nov. The type strain of Streptococcus ovis is CCUG 39485T (= LMG 19174T).
|
|
